ACON

Aclarion, Inc. develops and commercializes advanced medical imaging solutions for the diagnosis and treatment of chronic low back pain. Headquartered in Louisville, Colorado, the company's flagship product is NOCISCAN, a SaaS platform that uses magnetic resonance spectroscopy (MRS) biomarkers to identify the specific vertebral discs causing pain in patients. The technology aims to objectively identify painful discs prior to lumbar fusion surgery, addressing a significant unmet need in spine care where traditional imaging often fails to pinpoint the exact pain source. NOCISCAN integrates with existing MRI systems and provides physicians with biomarker data to support treatment decisions. Aclarion targets the chronic low back pain market, which affects millions of patients annually and represents billions in healthcare spending. The company operates on a commercial-stage business model, offering NOCISCAN to hospitals and imaging centers through service agreements. In recent developments, Aclarion has focused on expanding its commercial footprint, securing additional clinical sites, and pursuing reimbursement pathways to drive adoption. The company has published peer-reviewed research demonstrating NOCISCAN's ability to predict surgical outcomes and reduce unnecessary procedures. As a small-cap medical technology company, Aclarion continues to invest in clinical validation studies and regulatory activities to support broader market acceptance of its biomarker technology within the spine care community.